Serum protein N-glycome patterns reveal alterations associated with endometrial cancer and its phenotypes of differentiation

Front Endocrinol (Lausanne). 2023 Jun 26:14:1157487. doi: 10.3389/fendo.2023.1157487. eCollection 2023.

Abstract

Background: Aberrant N-glycosylation and its involvement in pathogenesis have been reported in endometrial cancer (EC). Nevertheless, the serum N-glycomic signature of EC remains unknown. Here, we investigated serum N-glycome patterns of EC to identify candidate biomarkers.

Methods: This study enrolled 34 untreated EC patients and 34 matched healthy controls (HC) from Peking Union Medical College Hospital. State-of-the-art MS-based methods were employed for N-glycans profiling. Multivariate and univariate statistical analyses were used to identify discriminative N-glycans driving classification. Receiver operating characteristic analyses were performed to evaluate classification accuracy.

Results: EC patients displayed distinct differences in serum N-glycome and had abnormal high-mannose and hybrid-type N-glycans, fucosylation, galactosylation, and linkage-specific sialylation compared with HC. The glycan panel built with the four most discriminative and biologically important derived N-glycan traits could accurately identify EC (random forest model, the area under the curve [AUC]=0.993 [95%CI 0.955-1]). The performance was validated by two other models. Total hybrid-type N-glycans significantly associated with the differentiation types of EC could effectively stratify EC into well- or poorly-differentiated subgroups (AUC>0.8).

Conclusion: This study provides the initial evidence supporting the utility of serum N-glycomic signature as potential markers for the diagnosis and phenotyping of EC.

Keywords: N-glycosylation; biomarker; diagnosis; endometrial cancer; mass spectrometry; serum N-glycome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Area Under Curve
  • Blood Proteins
  • Endometrial Neoplasms*
  • Female
  • Glycosylation
  • Humans
  • Phenotype

Substances

  • Blood Proteins

Grants and funding

This work was funded by grants from Capital’s Funds for Health Improvement and Research (Grant number 2022-1-4011), National High Level Hospital Clinical Research Funding (Grant numbers 2022-PUMCH-C-015 and 2022-PUMCH-A-200), and the National Natural Science Foundation of China (Grant number 32071436).